This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


The Human B Cell Response to a Repetitive Malaria Parasite Protein

This presentation will discuss how we use single-cell immunoglobulin gene repertoire analyses and antibody cloning to assess the quality of the human B cell response to a repetitive surface protein of the human malaria parasite Plasmodium falciparum with the long-term goal to use this knowledge for the development of targeted intervention strategies.

Hedda Wardemann, Ph.D., Professor and Head, Division of B Cell Immunology, German Cancer Research Center (DKFZ), Germany


Nanobodies: In Which Applications Will They Make a Difference?

Like many other man-made affinity reagents, Nanobodies are also robust, strictly monomeric and associate with high affinity and specificity to their cognate target. Most of the current Nanobodies were retrieved from relatively small immune libraries. From all affinity reagents and technologies, the identification of a lead Nanobody is most likely the most accessible and fastest. They are practical for biochemical research purposes, in diagnostics and therapy.

Serge Muyldermans, Ph.D., Professor, Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Belgium 

Finding the Right Antibody
Finding the Right Antibody

Profiling Disease-related Autoantibodies by NGS-based Peptidome-phage-display Screening

We combined peptide phage display with next generation sequencing to identify disease-related autoantibody profiles in a target-independent manner. A phage library of 3 million peptides covering the entire open reading frame of the human genome was designed. This peptidome library was successfully validated by screening with monoclonal antibodies and various plasma samples; a computational pipeline to process and analyze the data was established.

Andrée Rothermel, Ph.D., Authorized Officer and Director Biomarker Development Center, TRON and Principal Investigator, BioNTech Diagnostics GmbH, Germany 

Nano- and Chromobodies: How to Visualize and Quantify Proteins in Living Cells

Nanobodies have become highly valuable tools in biotechnology and medicine. Recently we have identified novel nanobodies for proteomics and super resolution microscopy. For in cellulo studies we developed intracellular functional nanobodies (chromobodies) to target and trace endogenous components in living cells. In combination with quantitative high-throughput microscopy and automated image analysis we applied chromobodies as intracellular nanoprobes for phenotypic screening and high-content imaging (HCI).

Ulrich Rothbauer, Ph.D., Professor for Pharmaceutical Biotechnology, University of Tuebingen/NMI, Germany 

Finding the Right Antibody
Finding the Right Antibody

Phage Display Selection of TCR-like Antibodies 

Phage display allows for identification of a multitude of specificities, but to isolate optimal lead candidates against specific members of the HLA ligandome still remains challenging. We have used a combination of in silico designed targeted libraries and stress-induced pIX phage display to develop picomolar affinity TCR-like antibodies allowing for high-resolution T cell epitope targeting.

Geir Åge Løset, Ph.D., CEO, Nextera AS, Norway


Array-based Proteomics

While mass spectrometry (MS) has tremendous analytical power, the technology is too slow and expensive to replace antibody-based methods such as western blotting (WB). In this presentation I will explain how standard separation techniques for native and denatured proteins can be combined with antibody array analysis to obtain multiplexing capacity and precision comparable to that obtained by MS.

Fridtjof Lund-Johansen, M.D., Ph.D., Senior Scientist, Immunology, Oslo University Hospital, Rikshospitalet, Norway